Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Moodys
Colorcon
McKinsey
AstraZeneca

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR DOCEFREZ


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Docefrez

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00075374 ↗ Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 2003-10-01 RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which docetaxel regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of docetaxel in treating patients who have not previously received chemotherapy for unresectable stage IIIB or stage IV non-small cell lung cancer.
NCT00075374 ↗ Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed Case Comprehensive Cancer Center Phase 2 2003-10-01 RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which docetaxel regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of docetaxel in treating patients who have not previously received chemotherapy for unresectable stage IIIB or stage IV non-small cell lung cancer.
NCT00260611 ↗ Study of Oxaliplatin and Taxotere in Prostate Cancer Completed Sanofi Phase 2 2004-11-01 The primary objective for this study is to evaluate PSA response rates (response will be defined as a > 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
NCT00260611 ↗ Study of Oxaliplatin and Taxotere in Prostate Cancer Completed University of Pittsburgh Phase 2 2004-11-01 The primary objective for this study is to evaluate PSA response rates (response will be defined as a > 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Docefrez

Condition Name

Condition Name for Docefrez
Intervention Trials
Prostate Cancer 4
Lung Cancer 2
Squamous Cell Carcinoma of the Head and Neck 1
Stomach Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Docefrez
Intervention Trials
Prostatic Neoplasms 5
Carcinoma, Non-Small-Cell Lung 4
Carcinoma 3
Lung Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Docefrez

Trials by Country

Trials by Country for Docefrez
Location Trials
United States 47
France 4
Taiwan 3
Spain 2
Israel 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Docefrez
Location Trials
Texas 7
Pennsylvania 4
Massachusetts 4
Missouri 3
Indiana 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Docefrez

Clinical Trial Phase

Clinical Trial Phase for Docefrez
Clinical Trial Phase Trials
Phase 3 1
Phase 2 9
Phase 1/Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Docefrez
Clinical Trial Phase Trials
Withdrawn 3
Recruiting 3
Terminated 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Docefrez

Sponsor Name

Sponsor Name for Docefrez
Sponsor Trials
Dana-Farber Cancer Institute 3
The University of Texas Health Science Center, Houston 2
Sanofi 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Docefrez
Sponsor Trials
Industry 12
Other 10
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.